GVK Biosciences has entered into a 50:50 joint venture (JV) with INC Research (INC) to establish a dedicated resource capability to offer phase I-IV clinical development programs in India for INC's global clients. The joint ventured company will be known as INC GVK Bio Pvt Ltd.

The joint venture will enable INC Research to conduct its global clinical trials in the areas of oncology, CNS, infectious diseases and Paediatrics, involving phase I-IV studies.

Commenting on the new initiative, G V Sanjay Reddy, CEO, GVK Bio said, "The joint venture provides an opportunity for the company to gain access to INC Research's global reach, leveraging its clinical research activities in India." Kelvin Logan, president of INC Research Europe said, "Our international base of operations has expanded strategically this year, with the addition of several new offices in Europe and now India. This joint venture will allow INC Research to further solidify and expand its presence within the world CRO market".

GVK Bio is one of India's premier contract research organisations, providing an integrated platform of research services across the pharma R&D value chain to a growing number of global pharma and biotech companies. The company combines science, innovation and resources to help clients address their drug discovery and development challenges. Currently, the company has more than 1,200 employees spread across facilities in Hyderabad, Chennai and Gurgaon.